From Elon Musk to several Hollywood celebrities, the weight loss wonder drug, semaglutide, is taking the world by storm. What was an unintended consequence of a diabetes control med, the emergence of significant weight loss has raised the expectation of the wonder drug becoming a $100 bn opportunity by 2030. While the drug’s innovator Novo Nordisk launched its oral version in India last year, Dr. Reddys Laboratories has now got approval to carry out bioequivalence studies of injectable semaglutide. So, what does this mean for India that has a huge disease burden of diabetes and obesity? Is the hype around the drug all worth it? Are there any side effects? Is it affordable? And who should be taking it? Host Kiran Somvanshi tries to understand from Dr. Ambrish Mithal, Chairman & Head - Endocrinology & Diabetes - Max Healthcare, and Nithya Balasubramanian, Director - AB Bernstein. Listen to the latest episode of The Morning Brief podcast!Disclaimer: The analyst interviewed has a
i m like really? all right. i can t wait to hear what people are going to say. thanks. here s what we have ahead. on the run down, forensic teams now are scrambling to identify what could be a serial killer s ninth victim. and burglars foiled, caught on video. japan s nuclear crisis, now officially on par with the disaster at chernobyl. plus, a combo pill that could be the new weight loss wonder drug. and i m going to put my shampoo and my conditioner into ziploc bags, and this fits much nicer. it kind of fits around the items that are in a bag. a flight attendant dishes on flying stress-free. ttd# 1-800-30